	US 12,070,458 B2
	Therapeutic agent composition and method of use, for treatment of mild congnitive impairment, depression, and psychological disorders
Lloyd Hung Loi Tran, San Jose, CA (US)
Filed by Lloyd Hung Loi Tran, San Jose, CA (US)
Filed on May 11, 2023, as Appl. No. 18/315,910.
Application 18/315,910 is a continuation of application No. 17/359,515, filed on Jun. 26, 2021, abandoned.
Application 17/359,515 is a continuation of application No. 16/412,759, filed on May 15, 2019, granted, now 11,090,303, issued on Aug. 17, 2021.
Claims priority of provisional application 62/674,855, filed on May 22, 2018.
Claims priority of provisional application 62/671,466, filed on May 15, 2018.
Claims priority of provisional application 62/671,485, filed on May 15, 2018.
Prior Publication US 2023/0381175 A1, Nov. 30, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4985 (2006.01); A61K 9/00 (2006.01); A61K 38/12 (2006.01); A61K 38/30 (2006.01); A61K 45/06 (2006.01); A61P 25/24 (2006.01); A61P 25/28 (2006.01)

CPC A61K 31/4985 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 38/12 (2013.01); A61K 38/30 (2013.01); A61K 45/06 (2013.01); A61P 25/24 (2018.01); A61P 25/28 (2018.01)]

19 Claims

1. A method of treating, relieving, or alleviating major depressive disorder in a mammal, comprising:

a) providing a mammal in need of treating, relieving, or alleviating major depressive disorder;

b) administering a pharmaceutically effective amount of cyclic Prolyl Glycine (cPG) or its analogues (cyclic(tri(Prolyl Glycine) or cyclic Glycyl-2-Allyl Proline, or cyclic Glycyl-Alkyl Proline or cyclic Glycyl-2-Methyl-Proline (cPMeG), or a combination thereof, collectively called a cPG compound, to said mammal;

wherein said mammal is treated, relieved, or alleviated of major depressive disorder.